CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 145 enrolled
Drug / intervention
Aricept (donepezil hydrochloride) +1 moredrug
Likely dose
Aricept (donepezil hydrochloride) 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00934375
NCT00934375Phase 4Completed
CompareCT.gov

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Eisai Inc.·interventional·Posted Jul 8, 2009·Updated Jan 14, 2014

In Brief

A Phase 4 clinical trial evaluating Aricept (donepezil hydrochloride) and placebo for Mild Cognitive Impairment. Completed, enrolled 145 participants across 49 sites.

Detailed Summary

This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 8, 2009
Enrollment StartFeb 1, 2006
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.0 years ago

Interventions

Aricept (donepezil hydrochloride)drug

5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.

placebodrug